Early Attempts: A Rocky Start
In the quest to slow or stop Alzheimer’s disease, drug development has centered for decades on amyloid plaques—sticky protein clumps that build up in the brain. The first monoclonal antibody drug to target them, aducanumab (Aduhelm), had a turbulent history. Large clinical trials were halted when the data didn’t show clear benefit. Despite this, the FDA granted accelerated approval in 2021, sparking controversy, and the drug was finally discontinued in 2024.

The New Generation
More recent drugs—lecanemab (Leqembi) and donanemab (Kisunla)—have shown modest promise. In people at the very earliest stage of Alzheimer’s, they appear to slow cognitive decline by about 25–30% over 18 months. That’s meaningful but far from a cure.

The bigger concern is side effects. These drugs can cause amyloid-related imaging abnormalities (ARIA)—a catch-all term for brain swelling (ARIA-E) and bleeding (ARIA-H). Many cases are mild and picked up on routine MRI scans, but some lead to seizures, dangerous brain hemorrhages, and in rare cases, even death. Risks are highest in people who carry two copies of the APOE4 gene and rise further for those on blood thinners. Because of this, regular brain scans are mandatory for anyone receiving treatment.

Another Dead End: BACE Inhibitors
At the same time, another class of drugs, called BACE inhibitors, came and went. Instead of helping, some of these drugs actually worsened cognition in clinical trials, forcing researchers to abandon the approach altogether.

Do Plaques Really Matter?
These mixed results have prompted many to ask: is amyloid really the right target? Increasingly, scientists think plaques may “set the stage,” while another protein—tau, which forms tangles inside neurons—triggers the cascade of symptoms. Supporting this, amyloid deposits can sometimes be found decades before memory problems arise, but once tau tangles spread, symptoms usually accelerate.

The Hopeful Side: Lifestyle Still Counts
While the pharmaceutical story is still unfolding, the evidence for lifestyle as a powerful ally has never been stronger.

Meditation
Simple, consistent meditation practices—like the 12-minute “Kirtan Kriya” from Kundalini yoga—have been shown to improve brain blood flow, sleep, and mood, while lowering stress and anxiety. Large reviews suggest meditation may build resilience, sharpen emotional regulation, and even slow the trajectory of cognitive decline (Alz Res Ther, 2018).

Yoga
Yoga offers its own brain benefits. In one study, just 10 weeks of Hatha yoga increased density in the hippocampus—a brain region central to memory. And after only 8 weeks of yoga practice, participants showed a reduced cortisol response to stressors and performed better on tests of attention and decision-making (Gothe et al., Brain Plasticity, 2019). In other words, yoga doesn’t just help people feel calmer—it actively strengthens the brain’s capacity to focus and regulate stress.

Aerobic Conditioning
Perhaps the most dramatic findings come from aerobic exercise. Activities like running, jogging, brisk walking, or swimming don’t just slow age-related brain shrinkage—they can actually grow the brain, even in seniors. A landmark study found that older adults who walked briskly for 40 minutes three times a week increased the size of their hippocampus by about 2% in one year, effectively reversing one to two years of normal atrophy (Erickson et al., PNAS, 2011). Aerobic activity boosts blood flow encourages the birth of new neurons and strengthens connections across brain networks.

Diet & Genetics
Food choices also play a major role. For people carrying two copies of the APOE4 gene—the highest known genetic risk—lifestyle can still shift the odds. A 2025 Nature Medicine study found that strict adherence to a Mediterranean-style diet reduced dementia risk by about 35%, even in APOE4 homozygotes. And when diet is combined with exercise, stress management, and mindfulness practices, the benefits appear to be additive, stacking up to a much greater overall reduction in risk.

The Takeaway
The new generation of anti-amyloid drugs represents progress, but with modest gains and serious risks. At the same time, everyday choices—how we move, how we eat, how we manage stress—have proven, lasting effects on brain health.

There may not be a single “magic bullet” for Alzheimer’s, but there is a powerful toolkit within reach: exercise, mindfulness, plant-forward diets, and stress reduction. These don’t just slow decline—they can literally reshape and strengthen the brain, offering hope at every age and stage.